Abstract Thiazolidinediones (TZDs) are eective for the treatment of adult-onset insulin-resistant diabetes. Unfortunately, TZDs are associated with sporadic hepatic dysfunction that is not predictable from experimental animal studies. We investigated the response of isolated rat and human hepatocytes to various TZDs using biochemical assays, coherent multiprobe¯uorescence microscopy and¯ow cytometric analyses. The results identi®ed direct eects of TZD on mitochondria from live human and rodent hepatocytes. The multiprobē uorescence assays showed disruption of mitochondrial activity as an initiating event followed by increased membrane permeability, calcium in¯ux and nuclear condensation. Other TZD-related cellular eects were increased hepatic enzyme leakage, decreased reductive metabolism and cytoplasmic adenosine triphosphate depletion. Mitochondrial eects were similar in cryopreserved hepatocytes from diabetic or non-diabetic donors. Peripheral blood mononuclear cells (PBMCs) had baseline mitochondrial energetics and metabolism comparable with isolated hepatocytes. Mitochondrial eects in isolated hepatocytes were found in human PBMCs exposed to the TZDs. The relative potency of TZDs for causing hepatocyte and PBMC eects was troglitazone >pioglitazone >rosiglitazone. These studies clearly demonstrated that hepatic alterations in vitro are characteristic of TZDs, with only quantitative dierences in subcellular organelle dysfunction. Monitoring mitochondrial function in isolated PBMCs may be bene®cial in diabetics undergoing TZD therapy.
Introduction
Thiazolidinediones (TZDs) comprise a group of drugs for the treatment of adult-onset insulin-resistant diabetes that increase insulin sensitivity, improve glucose control, and lower glycosylated hemoglobin 1 A, serum triglycerides and circulating insulin Iwamoto et al. 1991; Saltiel and Olefsky 1996; Schwartz et al. 1998) . In animal models of diabetes, including ob/ ob, K/K and db/db mice and Zucker fatty rats, TZDs reduced plasma glucose, insulin levels, ketone bodies, triglycerides and plasma lactate (Fujiwara et al. 1988) . The mechanisms by which cellular metabolic changes take place in diabetics are not fully understood, and glitazones activate the peroxisome proliferator-activated receptor c (PPARc) and modulate hepatic glucose transport, improve glucose utilization in skeletal muscle and cause pre-adipocyte dierentiation (Lehmann et al. 1995) . TZDs have been used eectively in a large number of diabetics, who, as a result, experienced signi®cant reduction of insulin requirements Iwamoto et al. 1991; Schwartz et al. 1998) . However, one compound in this class, troglitazone (see Fig. 1 ) caused sporadic hepatic dysfunction and hepatic failure in a number of cases (Watkins and Whitcomb 1998) . These reactions were not predictable from standard toxicological models Herman et al. 1997 Herman et al. , 1998 McGuire et al. 1997 McGuire et al. , 1998 Rothwell et al. 1997 ; M.M. Shi, M.R. Bleavins, R.G. Thompson, J.F. Chin and F.A. de la Iglesia, submitted for publication).
From the literature it is not possible to determine if these idiosyncratic reactions were due to altered biotransformation or conjugation mechanisms, a susceptible genotype, damaging drug metabolism interactions within the liver cell, or to decreased hepatic function as a result of pre-existing diabetic pathology (Cabarrou et al. 1973; Murakami and Shima 1995; Silverman et al. 1989) . Frequently, type II diabetics receive dierent concomitant medications for glucose control, hypertension, arthritis, pain and hypercholesterolemia (Tattersall 1995) . Compromised hepatic lipid or carbohydrate metabolism is not easily assessed in diabetics under current clinical laboratory protocols. These underlying diabetic alterations in the liver depend on advancing age, sex or coexisting pathology, such as hepatitis B or C, chronic cholestasis or alcoholism (Silverman et al. 1989) .
The eects of TZDs on human or animal live isolated hepatocytes have not been explored in detail. Mitochondria from diabetic Zucker rats lack the ability to compensate for chemically induced uncoupling of oxidative phosphorylation . To study the response of liver cell functions to pioglitazone, troglitazone and rosiglitazone, coherent multiprobe¯u-orescence assays have been used to determine time and dose relationships for decreased mitochondrial energetics, loss of plasma membrane integrity and altered calcium transport (Monteith et al. 1998 ; Plymale and de la Iglesia 1999; ). The multiprobē uorescence microscopy studies were followed by multiparameter¯ow cytometry in order to dissect the intracellular eects of TZDs on hepatocytes and peripheral blood mononuclear cells (PBMCs). Mitochondrial energetics, sulfation and glucuronidation are functions amenable for study in white blood cells or hepatocytes and have been explored with other drugs (Lowis and Oakey 1996) . Thus,¯ow cytometric evaluation of PBMCs from diabetics taking TDZ medication would constitute a minimally invasive, accurate and sensitive assay at a moderate cost together with the bene®t of predicting or preventing serious hepatic reactions.
Materials and methods

Hepatocyte isolation
Hepatocytes were isolated from 75-to 96-day-old female Wistar rats according to established methods with slight modi®cations (Deschenes et al. 1980; Seglen 1976) . Hepatocytes, puri®ed by dierential centrifugation through a Percoll gradient, were washed and suspended in Liebowitz L-15 hepatocyte culture media (Gibco Fig. 1 Structure of thiazolidinediones, related compounds and metabolites used in these studies BRL, Grand Island, N.Y., USA), supplemented with 7.5% bovine serum albumin, 1% penicillin/streptomycin, 3 mg/ml proline, 50 mg/ml galactose, 0.1% insulin-transferrin-selectin (Collaborative Biomedical Products, Bedford, Mass., USA), 0.4 mg/ml dexamethasone (Sigma, St. Louis, Mo., USA), 8.4% sodium bicarbonate and 0.1% trace elements. Viability of hepatocytes was assessed by Trypan blue exclusion. Plating was approximately 25,000 cells/well on 96-well collagen-coated plates and kept overnight at 37°C in a humidi®ed 5% CO 2 incubator for the assessment of enzyme leakage, and dimethylthiazol diphenyl tetrazolium (MTT) and adenosine triphosphate (ATP) assays. For coherent multiprobe¯uorescence microscopy, hepatocytes were plated at the same density on collagen-coated 8-chambered coverglasses (Nagle Nunc, Napervile, Ill., USA). Flow cytometry employed rat hepatocytes isolated as described above and normal or diabetic human hepatocytes obtained from In Vitro Technologies (Baltimore, Md., USA). Human and rat hepatocytes were suspended in Liebowitz media containing 5 lg/ml Hoechst 33342 and 100 nM tetramethylrhodamine ethyl ester (TMRE; Molecular Probes, Eugene, Ore., USA) and incubated for 25 min at 37°C in a humidi®ed 5% CO 2 -air interface prior to use. Incubation times, probe concentrations, and phototoxicity and photodegradation pro®les were optimized for¯ow cytometry or¯uorescence microscopy in preliminary experiments (data not shown).
Peripheral blood mononuclear cell isolation
Blood was collected from healthy volunteers and the red cells lysed in buer (150 mM NH 4 Cl, 1 mM EDTA and 10 mM NaHCO 3 (Sigma) for 10 min at room temperature. PBMCs were isolated after centrifugation at 300 g for 5 min and then suspended in RPMI-1640 media (StemCell Technologies, Inc., Vancouver, B.C., Canada) supplemented with 5% fetal bovine serum under the same conditions and probe concentrations as for hepatocytes.
Chemicals
Troglitazone, the quinone and sulfate metabolites, the tocopherol nucleus and the dione functional group, and rosiglitazone were dissolved in dimethyl sulfoxide (DMSO; Sigma) at 100 mM. Pioglitazone was prepared at 25 mM. All compounds were of ³95% purity. Appropriate dilutions were prepared from fresh stock solutions in Liebowitz or RPMI-1640 media. DMSO was reagent grade and the concentration did not exceed 0.06% in the preparations.
Selection criteria for in vitro concentration
The therapeutic concentration of troglitazone ranges from 1 to 2 lg/ml, equivalent to 2.25±4.5 lM; the drug is >99% protein bound and humans have signi®cantly lower blood concentrations than animals. (Kawai et al. 1997; Ott et al. 1998; Shibukawa et al. 1995) Troglitazone or pioglitazone at 20 lM inhibited transcriptional activity in ®broblast dierentiation assays in serum-free media (Ihara et al. 2001) . Troglitazone caused protein synthesis inhibition at 35±50 lM under serum-free conditions in human hepatocytes, and had inhibitory eects in sulfation-de®cient porcine hepatocytes beginning at 50 lM with 90% inhibition at 100 lM (Kostrubsky et al. 2000; Ramachandran et al. 1999) . Troglitazone inhibited gene expression of phosphoenolpyruvate carboxykinase and induced PPARc activation in hepatocytes and HepG2 cells at concentrations between 100 and 200 lM in serum-containing media (Davies et al. 1999a (Davies et al. , 1999b . ATP-dependent uptake of Neutral red was reduced by 80% under serum-free conditions with either 100 lM troglitazone or 100 lM rosiglitazone (Elcock et al. 1999) . Our preliminary experiments showed that troglitazone decreased mitochondrial transmembrane potential (DY m ) by 25% at 25 lM in serum-free conditions or at 300 lM in complete media, by 50% at 50 lM and 400 lM, and by 75% at ³100 lM and ³500 lM, respectively. Concentrations of ATP decreased by 80% with 225 lM troglitazone and by 60% with 450 lM rosiglitazone in serum supplemented systems. These data indicate that serum-free conditions will augment observed cellular responses and eects may appear at dierent concentrations. All assay conditions in this report include protein-supplemented cultures.
Enzyme leakage assays
Culture media with or without drug was added to triplicate plates and incubated for 2 h at 37°C. Each assay was repeated three times. Media and cell lysates were assayed for alanine aspartate aminotransferases (ALT), aspartate aminotransferases (AST) and lactic dehydrogenase (LDH) in a Vitros 750 XRC analyzer (Ortho Clinical Diagnostics, Raritan, N.J., USA).
MTT assay
Culture media with or without drug was added to plates and incubated for 2 h at 37°C and replaced with media containing MTT (0.5%) (Sigma). After an additional 2 h at 37°C, media was replaced with 100 ll of DMSO. Quadruplicate plates were read at 570 nm on a SpectraMax spectrophotometer (Molecular Dynamics, Sunnyvale, Calif., USA).
ATP assay ATP concentrations were measured using a luciferin-luciferase assay (ATP Lite-M kit; Packard, Meridien, Conn., USA). Cells were lysed and mixed with the substrate solution for 2 min, placed in the dark for 10 min and relative light units measured on a MLX microtiter plate luminometer (Dynex Technologies, Chantilly, Va., USA).
Coherent multiprobe¯uorescence microscopy
The coherent¯uorophore system was designed to follow time-related changes in DY m , intracellular Ca 2+ trac, plasma membrane permeability and nuclear cell morphology ). Cells were loaded with 100 nM tetramethylrhodamine methyl ester (TMRM), 4 U/ml BODIPY 650/665 Phalloidin, 2 lM Fluo-4 AM and 2 lg/ml Hoechst 33342 (Molecular Probes) in culture media for 30 min at 37°C. Media containing 4 U/ml BODIPY 650/665 Phalloidin and 2 lg/ml Hoechst 33342 was added after a brief wash. Four areas per well were selected for observation, based on TMRM¯uorescence threshold and ensuring a minimum of 80% viable cells. Treatment was initiated by adding an equal volume of media containing a 2´concentration of drug, 4 U/ml BODIPY 650/665 Phalloidin and 2 lg/ml Hoechst 33342. Digital images of the selected areas were captured every 10 min over 2 h. After appropriate photobleaching and phototoxicity validation protocols assured system stability and acceptance, the sequential exposures at each of the 10-min intervals were 3.0, 0.5, 0.75 and 0.25 s for Bopidy 650/665 phalloidin, TMRM, Fluo-4 and Hoechst 33342, respectively. The microscope was ®tted with a 100 W mercury lamp and 360/460, 480/535, 546/580 and 640/680 nm excitation/emission ®lters. A dierential interference contrast (DIC) image was obtained together with each of the¯uorescence image sequences to assess cell morphology. A high-resolution liquid-cooled chargecoupled device (CCD) was used to acquire over 2080 images over the 2-h period from each experiment. Average pixel intensities were calculated using the raw 12-bit image and applying an image analysis algorithm (Image Pro Plus, Media Cybernetics, Silver Springs, Md., USA).
Hepatocyte and PBMC¯ow cytometry
At the start of the experiment, equal volumes of media containing cells and media with 2´drug concentration were mixed and kept in a humidi®ed 5% CO 2 incubator at 37°C. For probe loading, cells were suspended in supplemented Liebowitz medium containing 5 lg/ml Hoechst 33342 and 100 nM TMRE and incubated for 25 min at 37°C. Aliquots of 15,000 cells were taken at 15-min intervals over 2 h and analyzed in an EPICS Elite¯ow cytometer (Beckman-Coulter, Miami, Fla., USA) with time-resolved 15-mW, 488-nm argon (upper) and 20-mW, 325-nm HeCd (lower) double excitation. Data collected from 15,000 cells were analyzed using WinList software (Verity Software, Topsham, Me., USA), which reported the number of cells with normal DY m . Light scatter was used to identify lymphocytes, monocytes and granulocytes.
Statistical analysis
Dierences between groups were determined by one-way analysis of variance (ANOVA) at a signi®cance level of 5%. Supplemental analyses of rank-transformed data were used when necessary. Sigma Stat v.2.0 for Windows (SPSS, Chicago, Ill., USA) was employed for all statistical analyses.
Results
Enzyme leakage in isolated rat hepatocytes
Troglitazone at concentrations ³400 lM caused LDH leakage of ³3 times the background (Table 1 ). The sulfate and the quinone metabolite, the tocopherol nucleus or the dione functional group, and rosiglitazone did not cause signi®cant enzyme leakage. ALT leakage of ³2 times background was seen with troglitazone at ³300 lM. The quinone metabolite at 600 lM caused a statistically non-signi®cant 1.7-fold increase in ALT leakage, with no other signi®cant increases found. At ³400 lM, troglitazone caused 5.4-to 6.5-fold increases in AST leakage.
Reductive metabolism in isolated rat hepatocytes Concentration-related decreases in reductive metabolism of MTT substrate was observed in troglitazone-treated rat hepatocytes. Reductive metabolism was similar to controls at 200 lM troglitazone, and decreased by 46%, 83%, 90%, and 89% at 300, 400, 500, and 600 lM, respectively ( Table 2 ). The quinone metabolite produced no changes in reductive metabolism up to 400 lM, and decreased metabolism by 52% and 79% at 500 and 600 lM, respectively. The sulfate metabolite, the dione functional group or the tocopherol moiety did not cause changes in reductive metabolism at any of the concen- Troglitazone quinone 200  241  342  163  300  252  332  164  400  261  341  173  500  261  294  151  600  302  4013  152   Troglitazone sulfate  200  252  293  142  300  232  293  132  400  252  322  143  500  252  325  152  600  262  344  163   Dione segment  200  232  244  132  300  232  3816  ±  400  243  263  111  500  232  273  132  600  222  284  142   Tocopherol segment  200  223  244  143  300  223  275  132  400  233  262  133  500  221  253  112  600  211  255  113   Rosiglitazone  200  222  265  131  300  242  243  142  400  242  304  162  500  262  284  162  600  304  273  161 a n=1 *Statistically signi®cant dierence from control (P<0.05) trations examined. In rosiglitazone-treated hepatocytes, reductive metabolism was comparable to controls at £ 500 lM, and decreased 46% at 600 lM.
Coherent multiprobe¯uorescence of rat hepatocytes
This approach provided quantitative analysis of¯uores-cence emissions captured in every ®eld. Control cultures showed no signi®cant changes in membrane permeability, nuclear morphology or intracellular Ca 2+ over the 120-min exposure period (Figs. 2, 3 and 4). Mitochondrial DY m decreased progressively to about 25±35% of baseline after 120 min, corresponding to a gradual loss of TMRM from hepatocytes. The concentrations tested were 200 lM and above since no eects were observed below this limit in preliminary experiments. The DY m pro®le with troglitazone at 200 lM was similar to that of control, at 300 and 400 lM DY m decreased 45±75% by 60 min and at 500 and 600 lM it decreased 75% from baseline in a hyperbolic function, with onset of changes within 10 min Fig. 2 Coherent multiprobe¯uorescence analysis of troglitazoneexposed rat hepatocytes. Concentration-related decreased DY m occurred as early as 10 min postdose at ³300 lM. Mitochondrial changes preceded the increased plasma membrane permeability noted 40 min postdose with ³400 lM. Nuclear condensation developed 100 min postdose at 500 and 600 lM. No eects on intracellular Ca 2+ occurred. Each point on the dierent curves represents the mean of eight measurements, equivalent to the average¯uorescence from a 50-to -70-cell ®eld. The relative standard error of each sample point ranged from 5 to 20% (Fig. 2) . Membrane permeability increased after 60 min at 400, 500 and 600 lM troglitazone. Increased nuclear uorescence, indicative of nuclear condensation, was seen after 100 minutes at 500 and 600 lM troglitazone. Cultures exposed to rosiglitazone behaved in a similar manner to controls with only a small increase in nuclear uorescence at 60 min with 600 lM (Fig. 3) . No nuclear or membrane permeability eects were seen with the troglitazone quinone (Fig. 4) , and DY m had decreased to 50% of baseline by 120 min at 600 lM. There were no signi®cant alterations in intracellular Ca 2+ with any of the compounds.
The time course of morphofunctional eects was further examined by reviewing both individual and fourcolor composite image sequences. An example of composite images from rat hepatocytes exposed to 300 lM troglitazone is found in Fig. 5 . At initiation (time zero), the ®eld contained numerous viable hepatocytes exhibiting high DY m (yellow) and prominent round nuclei (blue). A few compromised cells with signi®cant phalloidin staining (red) were visible. A loss of DY m was apparent in some cells by 30 min (arrows in Fig. 5 ). Flow cytometry of DY m in isolated rat hepatocytes Troglitazone, troglitazone quinone and rosiglitazone were evaluated at equimolar concentrations from 200 to 600 lM, a range that caused overt biochemical and morphofunctional toxicity (Tables 1 and 2 ). Mitochondrial DY m did not change in hepatocytes exposed to troglitazone at 200 lM, decreased 38±64% at 300 lM by 30±60 min and decreased approximately 75% within 15 min at ³400 lM (Fig. 6A) . No signi®cant DY m changes were seen with £ 400 lM troglitazone quinone; DY m decreased 21% at 500 lM by 60 min, reaching 42% at 120 min. Mitochondrial DY m decreased 24% by 30 min and 75% by 120 min at 600 lM (Fig. 6B) . Rosiglitazone caused no signi®cant changes in DY m at £ 500 lM; decreases of 26% occurred at 600 lM by 30 min and 55% by 60 min, remaining constant for the remaining 60 min (Fig. 6C) . A summary of the 60-min IC 50 for each compound in hepatocytes is found in Table 3 . Fig. 3 Coherent multiprobe¯uorescence analysis of rosiglitazoneexposed rat hepatocytes. Observed changes are small increases in nuclear condensation (indicated by increased nuclear¯uorescence). Condensation was signi®cant at 60 min postdose with 600 lM. Sampling and measurements as in Fig. 2 ATP levels in isolated rat hepatocytes Concentration-dependent decreases in intracellular ATP levels were observed in isolated rat hepatocytes treated with troglitazone (Fig. 7) . ATP concentrations were comparable to basal levels up to 100 lM troglitazone, decreased 20%, 56% and 88% at 150, 200 and 225 lM, respectively, and there was complete (>95%) ATP depletion at 250 lM and above. With rosiglitazone, gradual decreases in intracellular ATP levels were observed at 150±500 lM and up to 95% depletion occurred between 550 and 600 lM. (Fig. 7) . No signi®-cant alterations from basal ATP levels were found with 50 or 100 lM rosiglitazone.
Flow cytometry of DY m in isolated human hepatocytes
Mitochondrial DY m was monitored in normal human hepatocytes exposed to >100 lM troglitazone or rosiglitazone for 2 h (Fig. 8) . The 100 lM concentration represents several multiples of the therapeutic concentration in blood and one-to two-fold of the tissue concentration of the drugs. No signi®cant dierences were found from control values at the sampled intervals. Mitochondrial DY m of hepatocytes from one diabetic donor showed concentration-related decreases ranging from 14 to 25% at 50 and 100 lM troglitazone (Fig. 9A) . No eects were observed in the second diabetic donor or in the one exposed to rosiglitazone up to 100 lM (Fig. 9B,C) .
Flow cytometry of DY m in isolated human PBMCs
Troglitazone, troglitazone quinone, rosiglitazone and pioglitazone were evaluated for eects on DY m in isolated human PBMCs. Each compound was titrated through a series of concentrations that provided minimal and maximal responses in order to determine the IC 50 for the dierent cell types. Mitochondrial DY m was unchanged in lymphocytes at £ 50 lM troglitazone, decreased to 96% by 60 min at 100 lM and ³150 lM resulted in oblated DY m within 15 min (Fig. 10A) . Decreases of 23±77% in DY m were seen with 200±400 lM troglitazone quinone by 60 min, and 500±600 lM resulted in complete DY m depletion within 30±45 min (Fig. 10B ). Lymphocyte DY m showed no eects with 250 lM rosiglitazone, gradually decreased by 77±82% Fig. 4 Changes in coherent multiprobe¯uorescence caused by troglitazone quinone metabolite in rat hepatocytes. Signi®cant changes were decreases in DY m by 60 min postdose at 600 lM. No other cellular eects were seen. Sampling and measurements as in Fig. 2 by 60 min at 300±350 lM, and ³450 lM resulted in complete depletion within 15 min (Fig. 10C) . Mitochondrial DY m in lymphocytes was unchanged with £ 50 lM pioglitazone, and decayed by 20, 44, 76 and 98% at 100, 150, 200 and 250 lM, respectively. Pioglitazone at 300±350 lM decreased DY m 78±90% within 15 min and there was complete depletion by 30 min (Fig. 10D) . The 60-min IC 50 for each compound in lymphocytes is shown in Table 3 .
Granulocytes had no DY m changes with £ 10 lM troglitazone; 25 and 100 lM decreased DY m 26±37% within 15 min and control levels were observed by 60 min. In comparison, 150 lM caused 89% decreases by 15 min and resulted in complete DY m depletion by 15 min at ³200 lM (Fig. 10E ). Mitochondrial DY m did not change with troglitazone quinone at 200 lM, decreased by 15 min at ³300 lM and decreases reached 51, 69, and 96% at 300, 400 and 500 lM, respectively. At 600 lM, DY m was completely depleted by 30 min (Fig. 10F ). There were no DY m changes with rosiglitazone at 250 lM, and ³300 lM resulted in 15±30% lower DY m by 15 min, persisting to the end of the observation period (Fig. 10G ). Pioglitazone at £ 150 lM did not change DY m , and ³200 lM caused 10±33% reductions by 15 min that persisted for the rest of the test (Fig. 10H) . The 60-min IC 50 for each compound in granulocytes is shown in Table 3 .
Mitochondrial DY m in monocytes did not change with troglitazone at £ 25 lM, decreased 29±85% with 50±100 lM by 60 min, and complete signal loss occurred by 15 min at ³150 lM. (Fig. 10I) The troglitazone quinone did not cause DY m changes at 200±300 lM, decreased DY m by 98% after 60 min at 400 lM, with complete depletion within 15±30 min at 500±600 lM (Fig. 10J ). Rosiglitazone at 250 lM caused no changes, 300±350 lM decreased DY m 42± 67% by 60 min, and 34±76% at ³450 lM by 15 min with complete depletion by 60 min (Fig. 10K) . Monocyte DY m did not change with pioglitazone at £ 100 lM, decreased 35% by 15 min at 150 lM was within control levels by 30 min, and at 200 lM reached 59% reduction by 60 min. Concentrations above 250 lM caused complete DY m depletion within 45 min (Fig. 10L) . The 60-min IC 50 for each compound in monocytes is shown in Table 3 . Fig. 5 Time sequence of morphofunctional changes in isolated rat hepatocytes exposed to 300 lM troglitazone. The coherent multiprobe system was designed to follow DY m (TMRM, yellow), intracellular Ca 2+ (Fluo-4 AM,-green), plasma membrane permeability (Bodipy 650/665 phalloidin, red) and nuclear morphology (Hoechst 33342, blue). Numerous viable hepatocytes in yellow with prominent round nuclei (blue) and high DY m levels were seen at 0 min. Decreased DY m was noted in some cells as early as 30 min (arrows). Transient increases in intracellular Ca 2+ and blebbing were seen at 60 min in a few cells. Continued troglitazone exposure (90 min, 120 min) completely depleted DY m, and resulted in loss of plasma membrane integrity
Discussion
Type II diabetes is a multifactorial disease with diverse pharmacotherapies to control glucose levels, to improve insulin production or utilization and to compensate for alterations of lipid and carbohydrate metabolic (Galloway et al. 1988; Kahn et al. 2000; National Diabetes Data Group 1985 , 1987 Olefsky and Molina 1990) . TZDs, in general, have similar therapeutic pro®les, albeit with dierent relative potencies in the management of diabetics (Kameda et al. 2000; Kuehnle 1996; Oakes et al. 1994; Saltiel and Olefsky 1996; Sohda et al. 1992) . TZDs are therapeutically eective in type II diabetes and more than 1.5 million diabetics are prescribed these drugs but there is insucient information on the toxicity of this class. Although the mechanism of action is not well de®ned in humans, TZDs have liver cell eects that are not fully characterized and eects on cardiac muscle include glucose transport regulation and PPARc receptor activation. Thus, the clinical eectiveness or the toxicity of these drugs may be modulated by liver or muscle involvement (Kolaczynski and Caro 1998; Reginato and Lazar 1999) . Fig. 7 Kinetics of ATP depletion in isolated rat hepatocytes after exposure to troglitazone or rosiglitazone for 2 h. Rapid depletion of ATP was observed after troglitazone at ³150 lM, with complete depletion occurring at ³250 lM. Gradual depletion of ATP was seen following 200±500 lM rosiglitazone, with complete depletion at 550 and 600 lM. Results indicate dierences in the mechanism of nucleotide depletion. Each data point is the average of three separate experiments; the relative standard error of each sample point was <10% Fig. 6A±C Comparative analysis by¯ow cytometry of DY m in thiazolidinedione-exposed rat hepatocytes. Concentration-related decreases in DY m occurred with troglitazone (A), troglitazone quinone (B) and rosiglitazone (C). The 60-min IC 50 s were 270, 584 and 591 lM for troglitazone, troglitazone quinone and rosiglitazone, respectively. Each point on the dierent curves represents the mean relative¯uorescence distribution of 15,000 cells. The relative standard error of each gated-population ranged from 5 to 20% TZDs may have hepatic injury potential since the liver is a common target of pharmacology, biotransformation and toxicity of these drugs, and serious liver damage has been reported in patients taking TZDs. Liver injury, hepatic insuciency, hepatic transplantation or death ensued within a few weeks of troglitazone treatment. Liver injury consisted mainly of unexpected elevations of ALT and bilirubin, which in some cases were disproportionately high (Forman et al. 2000; Gitlin et al. 1998; Neuschwander-Tetri et al. 1998; Shibuya et al. 1998; Watkins and Whitcomb 1998) . The liver reaction to TZDs seems unpredictable, regardless of the clinical case or patient phenotype Iwamoto et al. 1991; Schwartz et al. 1998) . Elevated aminotransferases occur sporadically in diabetics (Sherman 1991 ) and the enzyme elevations may result from systemic drug accumulation, metabolic overload or hypersensitivity. Further, there are no dynamic molecular or cellular mechanisms that can account for the clinical toxicity of TZDs.
The studies reported here address in vitro responses of liver cells to TZDs under real-time conditions in order to understand the toxicity caused by these drugs. Most approaches to in vitro cellular toxicity monitor single parameters in live or ®xed cells . Recently, because of advances in¯uorescence technology, it became possible to monitor simultaneous intracellular events and to dissect pathways leading to cell dysfunction, injury and death. Coherent multiprobe¯uorescence microscopy provides sequential analyses of intracellular Flow cytometric detection of changes in DY m in thiazolidinedione-exposed human hepatocytes from diabetic donors. Concentration-related decreases in DY m were seen in hepatocytes from one donor exposed to troglitazone (A). No mitochondrial eects were seen with a second donor (B) or with hepatocytes from a third donor exposed to rosiglitazone (C). Each panel represents an individual diabetic donor and sampling as in Fig. 8 activities on a near real-time basis and uses speci®c functional¯uorescent probes that are coordinated in kinetic assays to reveal phenomena that otherwise are not observable in single time-point assays with ®xed or disrupted cells. The eects of tacrine, a drug that consistently caused increased liver transaminases in Alzheimer's patients, were characterized in human and animal hepatocytes with a three-probe assay ; Watkins et al. 1994) . Mitochondrial DY m was followed with tetramethylrhodamine, a sensitive indicator of mitochondrial function (Lemasters et al. 1998; Lemasters et al. 1999) . The decreased mitochondrial potential correlated with uncoupling of oxidative phosphorylation in isolated mitochondria (Monteith et al. 1998; . Plasma membrane integrity and cytoskeletal changes were monitored using conjugated phalloidin, a large molecular weight¯uo-rescent probe that remains in the media and covalently binds to F-actin monomers and¯uoresces after entering the cell. Fluo-4 AM is an indicator of cytoplasmic Ca 2+ tracking and nuclear morphology was followed using Hoescht 33342. The coherent use of these probes and spectral ®lters enabled the systematic monitoring of uorescence changes on a quantitative basis. A panel of four probes was used to de®ne the time course of intracellular events with TZDs.
Troglitazone above 200 lM decreased DY m initially with increased plasma membrane permeability, and Ca 2+ in¯ux was seen later. A series of assays for subcellular damage by dierent functional groups of the troglitazone molecule or metabolites showed no signi®-cant eects. The lack of eects by metabolites or functional groups and the sudden fall in intracellular ATP levels induced by troglitazone, suggest a rapid-onset and Fig. 10 Comparison of DY m changes in thiazolidinedione-exposed human peripheral blood mononuclear cells by¯ow cytometry. Concentration-related decreases in DY m were seen with troglitazone (A,E,I) and troglitazone quinone (B,F,J). For lymphocytes, granulocytes and monocytes, the 60-min IC 50 s ranged from 81 to 86 lM with troglitazone and between 303 and 319 lM with troglitazone quinone. Variable responses were seen in cells exposed to rosiglitazone (C,G,K) and pioglitazone (D,H,L). Respective IC 50 s were 284 and 166 lM in lymphocytes (C,D) and 395 and 177 lM in monocytes (K,L). Granulocytes were more resistant with IC 50 of >350 and >550 lM for pioglitazone (H) and rosiglitazone (G), respectively. Each data point represents the average measurement from four individual normal donors; the relative standard error for each sample point was <10% direct action. Microsomal incubations yielded the formation of oxidative scission products that were attributed a role in the toxicity mechanism (Kassahun et al. 2001) . Although the potential for toxicity exists, there are no available in-life studies that could corroborate these postulates. The oxidative metabolite formation is NADPH-dependent, and the role of such system in ATP-depleted and uncoupled intact liver cells has not been studied. Rosiglitazone decreased DY m less than troglitazone, and both drugs caused a fall in intracellular ATP. Thus, the DY m changes revealed unsuspected dierences and similarities between TZDs in liver cells that present an opportunity for further investigations. The early eects on mitochondrial energetics are due to irreversible uncoupling of oxidative phosphorylation. The toxicity of troglitazone has been attributed to the formation of a reactive quinone metabolite (Elcock et al. 1999) and to a quinone methide conjugate (Kassahun et al. 2001) . It is not known to what extent the liver cell can compensate or neutralize the oxidative damage from these compounds. The early onset of mitochondrial uncoupling and transmembrane potential loss caused by TZDs precede the appearance of metabolic biotransformation products that are detected in the bile. Multiprobe¯uorescence showed minimal DY m changes were induced by the quinone metabolite, with lesser or no eects on other cell functions. The ALT leakage was of borderline signi®cance and was corroborated by the lack of increased plasma membrane permeability. The DY m changes may explain the attenuation of eects by either troglitazone or the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) on mitochondria from Zucker diabetic female rats . Zucker diabetic rats have a pre-existing decreased DY m , and reduction of mitochondrial superoxide production controls hyperglycemic damage, an inherently bene®cial paradox (Nishikawa et al. 2000) . Diabetic mitochondria had no further decreases in DY m after troglitazone, but the overall transmembrane potential remained lower than controls.
The eects of troglitazone and rosiglitazone on cryopreserved hepatocytes from normal or diabetic humans were explored and the samples showed the range of mitochondrial changes in diabetic livers. Since cryopreservation may have aected some sensitive energydependent functions, data from freshly isolated liver cells exposed to TZDs would be useful to con®rm our results. Troglitazone-related DY m changes in human diabetic hepatocytes were comparable to those in normal rat liver cells, suggesting similar mechanisms of injury at the cellular level in humans and rats. Peroxidative damage to mitochondria may contribute to the development of diabetic complication (Nishikawa et al. 2000) but data are lacking to compare DY m from diabetic animals receiving TZDs.
While studying the mechanism of TZD-mediated hepatocyte injury, it was desirable to develop a marker of cellular eects that would be applicable to the clinical setting. Animal studies did not reveal clinical or pathological evidence of liver changes in troglitazone long-term studies, as opposed to the short-term onset of hepatotoxicity in humans. Rodents and monkeys metabolize troglitazone in a similar manner to humans and were given large daily doses in chronic studies without signs of clinical liver reactions or microscopic liver injury (Herman et al. 1997; McGuire et al. 1997; Rothwell et al. 1997) . Changes in DY m , however, are characteristically reproducible across species with quantitative dierences being a function of species-speci®c compensatory mechanisms. It is only recently that the mitochondrial transmembrane potential appears as an early and sensitive indicator of damage, is accompanied by ATP depletion and is followed by increased membrane permeability. Future studies should address the downstream eects of these changes, since nuclear condensation and apoptosis are observed as late eects that are shared by TZDs.
Functional mitochondrial markers in serially sampled cultures of human PBMCs exposed to TZDs mimicked the eects seen in human or animal liver cells by¯ow cytometry. Mitochondrial DY m changes were consistently reproducible in rapid and simple assays in discrete white blood cell populations with the IC 50 as a sensitive index. Thus,¯ow cytometry represents a practical and easily available technology that many laboratories could apply to monitor cellular eects of potential toxicants. We propose that monitoring the early toxicity indicator DY m in white blood cells should become available to diabetics in order to anticipate or prevent adverse hepatic reactions.
